Table 2.

Selected series with factors influencing OS and local control in patient treated with HFRT.

	Overall survival		Local control
	SS	NS	SS	NS
Ebner et al. (15)	UVA: Age (<65 years) Controlled primary MVA: Age <65 years	Size: <3.0 cm vs. ≥3 cm		UVA: Gender Age ≥65 Histology Surgical resection status Dose (≤16 vs. >16 Gy) Tumor size: 3–4 cm vs. ≥4 cm
Inoue et al. (40)	Lower survival for lesions ≥ 30 cm3			On UVA and MVA: Age Gender Tumor location within brain Tumor volume Number of fraction of RT V14 Tumor size: 10–19.9 cm3 vs. 20–29.9 cm3 vs. ≥ 30 cm3
Fokas et al. (38)	UVA: Chemotherapy status (yes vs. no) RPA class: I vs. II-III Single BM (vs. multiple BM) Presence of extracerebral disease MVA: RPA class I	Surgical resection status Age Gender	Dose administered (srs vs. 7X 5gy vs. 10X 4gy)
Jiang et al. (13)	Controlled primary tumor KPS≥ 80	Gender Age Number of brain mets presence of extracranial disease RPA class		Gender Age number of brain mets presence of extracranial metastasis KPS RPA class
Minniti et al. (12)	MVA: Extracranial disease (stable) Histology: breast cancer (better) KPS >70		Histology: melanoma worse local control	No other actors were predictive of local failure; Tumor size > 3 cm was of borderline significance
Navarria et al. (7)	UVA and MVA: KPS Extracranial disease (stable)		UVA and MVA: Gender Age KPS Histology Presence of extracranial disease RPA-GPA class Tumor size
Yomo and Hayashi (42)	Extracranial disease (stable) Interval from cancer diagnosis to RT treatment (<12 vs. > 12 months) Single vs. multiple BM	Age (≤65 vs. >65) KPS ≥90
Fahrig et al. (37)	MVA: RPA class	MVA: RT dose (5 X 7Gy vs. 10X 4Gy vs. 7 X5gy)	Trend for better LC for lesions treated with 5X6-7Gy and 7X5Gy vs. 10X4Gy
Ernst-Stecken et al. (36)	Tumor size KPS Number of metastases (1 vs. >1)	Extracranial disease Age (≤65 vs. >65) Gender
Angelov et al. (3)	UVA: Interval from cancer diagnosis to RT treatment (<12 vs. > 12 months) KPS (<70) Number of lesions <2 cm Greater volume of tumor present at second hypofx treatment (≤3.5 vs. >3.5 cm3) MVA: KPS Number of lesions <2 cm greater volume of tumor present at second hypofx treatment (≤3.5 vs. >3.5 cm3)		UVA: Volume change between first and second hypofx treatment KPS MVA: Volume change between first and second hypofx treatment

SS, statistically significant; NS, non-statistically significant; RPA, recursive partitioning analysis; KPS, Karnofsky Performance Score; GPA, graded prognostic assessment; UVA, univariate analysis; MVA, multivariate analysis; BM, brain metastasis.